Pharmaceutical composition

A method for manufacturing a pharmaceutical composition, comprising forming an admixture comprising an insulin sensitivity enhancer and a biguanide, wherein the insulin sensitivity enhancer is selected from the group consisting of:

• (a) 5-[4-[2-(3-ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione or its pharmacologically acceptable salt,
• (b) 5-[4-[2-(4-ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione or its pharmacologically acceptable salt,
• (c) 5-[4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione or its pharmacologically acceptable salt,
• (d) 5-[4-[2-(6-ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione or its pharmacologically acceptable salt,
• (e) (R)-(+)-5-[3-[4-(2-(2-furyl)-5-methyl-4-oxazolylmethoxy]-3-methoxyphenyl]propyl]-2,4-oxazolidinedione or its pharmacologically acceptable salt,
• (f) 5-[[3,4-dihydro-2-(phenylmethyl)-2H-1-benzopyran-6-yl]methyl]-2,4-thiazolidinedione or its sodium salt,
• (g) 5-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)-1-oxopropyl]phenyl]methyl]-2,4-thi azolidinedione or its sodium salt,
• (h) 5-[2-(5-methyl-2-phenyl-4-oxazolylmethyl)benzofuran-5-ylmethyl]-2,4-oxazolidinedione,
• (i) 5-(2-naphthalenylsulfonyl)-2,4-thiazolidinedione, and
• (j) 5-[[4-(2-methyl-2-pyridylamino)ethoxy)phenyl]methyl]-2,4-thiazolidinedione or its pharmacologically acceptable salt.